Bill

HB 3148

86(R) - 2019
House Public Health
Senate Health & Human Services
House Public Health
Senate Health & Human Services

Vote Recommendation

Neutral
  • Neutral
  • Neutral
  • Neutral
  • Neutral
  • Neutral

Author(s)

Tan Parker

Sponsor(s)

Paul Bettencourt

Bill Caption

Relating to the administration and oversight of investigational adult stem cell treatments administered to certain patients.

Fiscal Notes

According to the Legislative Budget Board, no fiscal impact to the state is anticipated. 

Bill Analysis

HB 3148 would require the Department of State Health Services (DSHS) to establish and maintain an investigational stem cell registry that lists each physician who administers an investigational stem cell treatment, as well as adopt a form for informed consent. It would also require an institutional review board that oversees investigational stem cell treatments to meet certain conditions.

Additionally, this bill would prohibit a governmental entity from interfering with an eligible patient's access to or use of an investigational stem cell treatment unless the treatment uses an adult stem cell product that is considered an adulterated or misbranded drug. It would also prohibit a governmental entity from considering the adult stem cell product to be an adulterated or misbranded drug solely on the basis that the U.S. Food and Drug Administration has not approved it.

Vote Recommendation Notes

Institutional review boards that oversee investigational adult stem cell treatments are already subject to certain affiliation requirements. HB 3148 does not appear to affect our liberty principles and we remain neutral.